Daiichi Sankyo (OTCPK ... its antibody-drug conjugate Dato-DXd marketed with AstraZeneca (NASDAQ:AZN) as a late-line option ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody ... approve the ADC in non-small cell lung cancer. Like in breast cancer, Dato-DXd failed to improve OS but did move the needle on ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

AstraZeneca and Daiichi Sankyo have claimed ... datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast cancer, a few weeks after ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has ... certain advanced breast cancer patients. Datroway, also called datopotamab deruxtecan, or Dato-DXd, was approved ...

The drug, known in development as datopotamab deruxtecan, or Dato-DXd ... of many types of cancer cells, including breast cancer cells. The AstraZeneca/Daiichi Sankyo drug was evaluated in ...

AstraZeneca ... metastatic breast cancer, remains under review by the EMA and is based on the TROPION-Breast01 Phase III trial. Datopotamab deruxtecan was discovered by Daiichi Sankyo and is ...

THP in HER2+ metastatic breast cancer in DESTINY ... discovered by Daiichi Sankyo DSNKY DSKYF and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast cancer.

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a first-line breast cancer trial, the companies have scored again in another ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of lung cancer ... with Daiichi Sankyo on the drug, has cited Dato ...